Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults

BACKGROUND: In the ZOE-50 and ZOE-70 clinical trials, the candidate herpes-zoster subunit vaccine (HZ/su; 50µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) demonstrated high efficacy against HZ, with limited waning over 4 years and consistent efficacy across age cohorts. I...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Open Forum Infect Dis
Glavni autori: Pauksens, Karlis, Volpe, Stephanie, Schwarz, Tino F, Smetana, Jan, Toursarkissian, Nicole, Rombo, Lars, Ravault, Stéphanie, David, Marie-Pierre, Bastidas, Adriana, Oostvogels, Lidia
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631129/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1039
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items